SU614746A3 - Method of obtaining prostaglandine analogue - Google Patents
Method of obtaining prostaglandine analogueInfo
- Publication number
- SU614746A3 SU614746A3 SU762334454A SU2334454A SU614746A3 SU 614746 A3 SU614746 A3 SU 614746A3 SU 762334454 A SU762334454 A SU 762334454A SU 2334454 A SU2334454 A SU 2334454A SU 614746 A3 SU614746 A3 SU 614746A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- formula
- ethyl
- acid
- methyl
- solution
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- -1 triphenyl-2-oxoheptylphosphoric chloride Chemical compound 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 claims 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- OOBFNDGMAGSNKA-UHFFFAOYSA-N ethyl 7-bromoheptanoate Chemical compound CCOC(=O)CCCCCCBr OOBFNDGMAGSNKA-UHFFFAOYSA-N 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 238000002474 experimental method Methods 0.000 claims 1
- 239000005457 ice water Substances 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- XWCQLLDGXBLGMD-UHFFFAOYSA-M magnesium;pentane;bromide Chemical compound [Mg+2].[Br-].CCCC[CH2-] XWCQLLDGXBLGMD-UHFFFAOYSA-M 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000012074 organic phase Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229940072033 potash Drugs 0.000 claims 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 1
- 235000015320 potassium carbonate Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012047 saturated solution Substances 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 229910001961 silver nitrate Inorganic materials 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- QYJOOVQLTTVTJY-UHFFFAOYSA-N Ethyl pyroglutamate Natural products CCOC(=O)C1CCC(=O)N1 QYJOOVQLTTVTJY-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- QYJOOVQLTTVTJY-YFKPBYRVSA-N ethyl (2s)-5-oxopyrrolidine-2-carboxylate Chemical compound CCOC(=O)[C@@H]1CCC(=O)N1 QYJOOVQLTTVTJY-YFKPBYRVSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/04—Saturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/16—Saturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
- C07C51/38—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by decarboxylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5407—Acyclic saturated phosphonium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
(54) СПОСОБ ПОЛУЧЕНИЯ АНАЛОГА ПЬХЮТАГЛЛИДИИА(54) METHOD OF OBTAINING ANALOGUE PHUHUTAGLLIDIA
II
Иэобрегенне относитс к способу получени не описанного в литературе аналога простаглаидина формулыIobregenne does not relate to a method for producing a prostaglaidin analogue of the formula not described in literature.
Предлагаемый способ получени aiianoi-,i простагландина заключаетс в rovf, что (;лс жный эфир обшей формулы 1The proposed method for the preparation of aiianoi-, i prostaglandin consists in rovf that (; ester of the general formula 1
СООНCun
соонsoon
10ten
онhe
обладающего фармакологической активностью.with pharmacological activity.
Известен способ получени карбоновых кислот с помощью щелочного гидролиза сложных эфиров ij.A known method for producing carboxylic acids by alkaline hydrolysis of esters ij.
Использование известной реакции позвол ет получать новое производное простаглаи-20 диИа, про вл ющее фармакологическую активность.The use of a known reaction allows the preparation of a new prostaglai-20 diIa derivative exhibiting pharmacological activity.
иель изобретени - расщиреиие ассортимеита биологически активных соедииеинй. 25The invention of the invention is the expansion of the assortite of biologically active compounds. 25
в которой и представл ет собой линейшлй или разветвленный алкнльиый радикпл, содержащий 1-7 атомов углерода, пооверглюг взаимодействию с гидроокисью щелочно1Х металла в спиртовой среде при комнатной температуре с последующей обработкой сил ной кислотой.in which it represents a linear or branched alkali radikpl containing 1-7 carbon atoms, interacting with an alkali metal hydroxide in an alcohol medium at room temperature followed by treatment with strong acid.
Соединени формулы Т, в которой Tt п|х.лставл ет ообой метил нли этил, могут быть получены восстанхжлением 3)L - uu-карбометокси- или карбэтокси-1-гексип-5-(3-(Ж(:о-1-октен- Еj-Bin )-2-пирролидинона обшей формулы ДCompounds of formula T in which Tt p | x. Represents methyl methyl or ethyl can be obtained by reduction 3) L - u-carbomethoxy or carbethoxy-1-hexyp-5- (3- (W (: o-1- octene-Ej-Bin) -2-pyrrolidinone of the general formula D
ClOORCloor
R которой Т -метил или атнл, с помощью подход щего восстановител , например бо(гидрида натри , в инертной среде, например диметокснэтане, при , предпочтительно 0°С.R of which T is methyl or atnl, using a suitable reducing agent, for example bo (sodium hydride, in an inert medium, for example dimethoxynethane, with, preferably 0 ° C.
Соединени могут быть получены из DI -пироглутаминовЫ кислоты ф( мулыCompounds can be obtained from DI-pyroglutamic acids f (mules
(J(J
7«Н7 "H
Соон Soon
этерификацией последней этанолом в присутствии кислоты, например п олуолсуль- фоювой, получают этил-пироглутамат формулыby esterification of the latter with ethanol in the presence of an acid, for example, p-olusulfonic, ethyl pyroglutamate of the formula
ОABOUT
NHNH
ид.id
который затем восстанавливают б гидрндом натри в растворвтело,. например метаноле, получа (жсиметил-2-пирропидинон формулыwhich is then reduced with sodium hydrnd in solution, in body ,. for example, methanol to obtain (zsimethyl-2-pyrropidinone of the formula
IоIo
тшtsh
i-Li-l
СНгОНSNGON
Затем это соединение подвергают взаимо Действию с 2,3-дигндрс«тираном в инертной среде, например хлористом метилене, в присутствии кислоты, например ,п- олуолсуль- фоновой, и получают DU -5-(гвтрагидр пиранил-2-сжсиметил )-2-пирролидинон формулыThis compound is then reacted with a 2,3-diggers "tyrant in an inert medium, for example, methylene chloride, in the presence of an acid, for example, p-oluolsulfonic), to give DU-5- (pyrayl-2-ssimethyl) -2 -pyrrolidinone formula
ОABOUT
IXIx
«„о""about
который обрабатывают метил- или 9тил-7-бромгептаноатом обшей which is treated with methyl or 9-7-bromoheptanoate sheath
)4Вг,) 4Vg,
где R имеет те же значени , что и в формуле JT , в инертном растворителе,, предпочтительно толуоле, в присутствии амида натри , и выдел ют соединени общей формулы jjwhere R has the same meaning as in formula JT, in an inert solvent, preferably toluene, in the presence of sodium amide, and compounds of the general formula jj are isolated
СООЕ Sooe
СИ, о-/ЛSI, o- / l
Ов которой т имеет те же значени , что и в формуле Н .Oh which t has the same meaning as in the formula.
3)Ь-и;-Карбометокси- или карбэтокси-1-гексил-51 тетрагндропйранил-2-сжсиметил)- -2-пирролидинон формулы Ц гидропиауют в кислой среде, например в сс п ной кислоте , в присутствии растворител , например метанола, и получают I)L -ч -карбометокси- или карбэтокси-i-гексил-б-оксиметил- -2-пирролидинон обивй формуль 3) L-and; -Carbomethoxy- or carbethoxy-1-hexyl-51 tetrahydropyranyl-2-ssimethyl) -2-pyrrolidinone of the formula C is hydropiated in an acidic medium, for example, with sulfuric acid, in the presence of a solvent, for example methanol, and get I) L-h -carbomethoxy- or carbethoxy-i-hexyl-b-hydroxymethyl -2 -2-pyrrolidinone obiv formul
эоeo
С ООНFrom the UN
3535
СНгОнSNGon
в которой т имеет те же значени , что и в формуле Я , затем первичный спирт, окисл ют до альдегида в инертной среде, например бензоле, при комбинированном воздействии диметилсульфоксида, дициклогексилкарбодиимида и дихлоруксусной кисS лоты, получаю т Ли-Ш-карбометокси- или карбэтокси-1-гексил-5-«арбоксальдегид-2-пирролидинон формулыwherein t has the same meaning as in formula I, then primary alcohol, is oxidized to the aldehyde in an inert medium, for example benzene, when combined with dimethyl sulfoxide, dicyclohexylcarbodiimide and dichloroacetic acid, get t-Li-Sh-carbomethoxy or carbethoxy -1-hexyl-5- "arboxaldehyde-2-pyrrolidinone of the formula
COORCOOR
СноSno
5Л В которой т имеет те же значени , что и в формуле Д . Альдегидную группу в синтезированном соединении подвергают реакции Виттига с 1-трифени/|фосфоранилиден-2-геитаноном формулы IV5L In which m has the same meanings as in formula D. The aldehyde group in the synthesized compound is subjected to the Wittig reaction with 1-tripheny / phosphoranylidene-2-geitanone of formula IV
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB12034/75A GB1529852A (en) | 1975-03-21 | 1975-03-21 | 8-azaprostaglandins and process for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SU614746A3 true SU614746A3 (en) | 1978-07-05 |
Family
ID=9997230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU762334454A SU614746A3 (en) | 1975-03-21 | 1976-03-19 | Method of obtaining prostaglandine analogue |
Country Status (26)
Country | Link |
---|---|
JP (1) | JPS607602B2 (en) |
AR (1) | AR213172A1 (en) |
AT (1) | AT348163B (en) |
AU (1) | AU501105B2 (en) |
BE (1) | BE839761A (en) |
CA (1) | CA1076587A (en) |
CH (2) | CH611881A5 (en) |
DE (1) | DE2612114A1 (en) |
DK (1) | DK140937B (en) |
ES (2) | ES446239A1 (en) |
FI (1) | FI61692C (en) |
FR (1) | FR2304340A1 (en) |
GB (1) | GB1529852A (en) |
HU (1) | HU173348B (en) |
IE (1) | IE42966B1 (en) |
IT (1) | IT1061011B (en) |
MX (1) | MX3301E (en) |
NL (1) | NL7602891A (en) |
NO (1) | NO144147C (en) |
NZ (1) | NZ180251A (en) |
OA (1) | OA05279A (en) |
PT (1) | PT64919B (en) |
SE (1) | SE418290B (en) |
SU (1) | SU614746A3 (en) |
YU (1) | YU73876A (en) |
ZA (1) | ZA761448B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4097489A (en) * | 1977-06-17 | 1978-06-27 | The Upjohn Company | 9-Deoxy-9α,6-nitrilo or 6,9α-imino-PGF compounds |
US5540618A (en) * | 1994-10-28 | 1996-07-30 | National University Of Singapore | Passive attenuator for shelter protection against explosions |
WO2003074483A1 (en) | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
-
1975
- 1975-03-21 GB GB12034/75A patent/GB1529852A/en not_active Expired
-
1976
- 1976-03-02 DK DK88276AA patent/DK140937B/en not_active IP Right Cessation
- 1976-03-09 ZA ZA761448A patent/ZA761448B/en unknown
- 1976-03-09 NZ NZ180251A patent/NZ180251A/en unknown
- 1976-03-11 AU AU11899/76A patent/AU501105B2/en not_active Expired
- 1976-03-15 IE IE545/76A patent/IE42966B1/en unknown
- 1976-03-17 AT AT195676A patent/AT348163B/en not_active IP Right Cessation
- 1976-03-18 IT IT21346/76A patent/IT1061011B/en active
- 1976-03-18 SE SE7603400A patent/SE418290B/en unknown
- 1976-03-18 FR FR7607794A patent/FR2304340A1/en active Granted
- 1976-03-18 PT PT64919A patent/PT64919B/en unknown
- 1976-03-19 CH CH844678A patent/CH611881A5/en not_active IP Right Cessation
- 1976-03-19 YU YU00738/76A patent/YU73876A/en unknown
- 1976-03-19 AR AR262630A patent/AR213172A1/en active
- 1976-03-19 CH CH350176A patent/CH611604A5/en not_active IP Right Cessation
- 1976-03-19 BE BE165326A patent/BE839761A/en not_active IP Right Cessation
- 1976-03-19 CA CA248,275A patent/CA1076587A/en not_active Expired
- 1976-03-19 HU HU76LA885A patent/HU173348B/en unknown
- 1976-03-19 FI FI760744A patent/FI61692C/en not_active IP Right Cessation
- 1976-03-19 SU SU762334454A patent/SU614746A3/en active
- 1976-03-19 NL NL7602891A patent/NL7602891A/en not_active Application Discontinuation
- 1976-03-19 NO NO760994A patent/NO144147C/en unknown
- 1976-03-19 MX MX000100U patent/MX3301E/en unknown
- 1976-03-20 ES ES446239A patent/ES446239A1/en not_active Expired
- 1976-03-20 OA OA55774A patent/OA05279A/en unknown
- 1976-03-22 DE DE19762612114 patent/DE2612114A1/en not_active Withdrawn
- 1976-03-22 JP JP51031889A patent/JPS607602B2/en not_active Expired
-
1977
- 1977-05-03 ES ES458389A patent/ES458389A1/en not_active Expired
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI77847C (en) | Process for the preparation of therapeutically useful alkoxy acid derivatives. | |
US4119727A (en) | Novel 11-desoxy-prostaglandin F2 derivatives | |
KR20140027905A (en) | Processes for preparation of lubiprostone | |
SU614746A3 (en) | Method of obtaining prostaglandine analogue | |
SU727139A3 (en) | Method of preparing optically active 11-desoxy-16-aryl-omega-tetranorprostaglandines or their racemates or their salts | |
US3883659A (en) | 9-Oxaprostaglandin compositions | |
US3806540A (en) | Unsaturated carboxylic acid esters | |
US4317920A (en) | Arylacetic acid derivatives | |
US4076732A (en) | Derivatives of α-(6-carboxyhexyl) furfuryl alcohol | |
US4568762A (en) | 4-Methyl-2-oxo-cyclopentylidene acetic acid and esters thereof | |
JPH0774194B2 (en) | A novel actinonine derivative with physiological activity | |
EP0640579B1 (en) | Process for producing optically active 2-norbornanone | |
JPS6317077B2 (en) | ||
US4009172A (en) | 2,3,3A,6,7,7A-Hexahydro-thieno[3,2-b]pyridin-(4H)5-ones | |
US4103091A (en) | Method for the preparation of prostaglandin intermediates from a mold metabolite | |
US4277401A (en) | Total synthesis of 1RS,4SR,5RS-4-(4,8-dimethyl)-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicyclo[3.2.1]octane-1-acetic acid | |
US5169959A (en) | Free radical-catalyzed synthesis of benzoprostacyclins | |
US4408066A (en) | Methyl cyclopropane-1,3-dicarboxylate | |
US4188329A (en) | Intermediates for the preparation of prostaglandins and prostaglandin analogs from a mold metabolite | |
US3681391A (en) | 1,6 oxidocyclodecapentaene alcohols, aldehydes, and acids | |
US4385004A (en) | Esters of ortho-allylphenol useful for the preparation of arylacetic acid derivatives | |
SU385428A1 (en) | METHOD OF OBTAINING DERIVATIVE ALIPHATIC HALOGEN-CONTAINING UNSATUROUS ACIDS | |
JP6345499B2 (en) | Process for the preparation of (2-hydroxy-3-oxo-cyclopent-1-enyl) -acetate | |
USRE29587E (en) | Cyclopentanone derivatives | |
US3694472A (en) | Synthesis of pyrethric acid |